Company intelligence / Profile preview

Defender Pharmaceuticals, Inc.

St. Louis, Missouri, United Statesdefenderpharma.com ↗

Ownership: Private
Development stage: Commercial

Overview

Defender's lead product DPI-386 (intranasal scopolamine gel) received a Complete Response Letter from the FDA in January 2024 for its NDA for prevention of motion sickness. The company had previously received priority review status for this application at the request of the U.S. Navy with a PDUFA date of January 26, 2024[4][8].

Therapeutic areas: OtherPsychiatryNeurologyInfectious Diseases
Modalities: Small moleculesVaccines
Industry: Biotech

Drug pipeline

7 assets

placebo gel (Naval Aeromedical Research Unit, Dayton)

6 more assets in the full pipeline.

Request access →

Partnerships

U.S. NavyNASAU.S. Army Medical Materiel Development Activity (USAMMDA)United States Naval Medical Research Unit (NAMRU-D)

Beyond the preview

Go deeper on Defender Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Defender Pharmaceuticals, Inc..

Explore the full profile